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INTRODUCTION
Primary CNS lymphoma accounts for 3% of all primary
brain tumours with median age of onset of about 62
years.1 The disease is more common in men (the male-
to-female ratio is 2:1). The nature, intensity, and duration
of immune suppression are factors in determining the
risk of developing PCNSL.  Patients with AIDS who have
low CD4+ counts are at the greatest risk for PCNSL. It is
an aggressive form of non-Hodgkin's lymphoma that
develops within brain, spinal cord, eye or leptomeninges
without evidence of systemic involvement. In majority of
the cases, it presents as unifocal and multifocal
enhancing lesions on MRI, frequently adjacent to
ventricles. Biopsy is the diagnostic procedure of choice
revealing high-grade malignant non-Hodgkin’s B-cell
lymphoma in more than 90% cases. Pathologically, it is
an angiocentric neoplasm composed of a dense
monoclonal proliferation of lymphocytes usually diffuse
large B cells.2 Despite recent progress, results following
the treatment for primary CNS lymphoma patients
remain disappointing, typically producing a 5 years
survival rate of 22-40%.3 Chemotherapy followed by
radiotherapy is the cornerstone of first line treatment of
primary CNS lymphoma.4,5 The principal agent in its
management is high dose methotrexate (HD MTX)
which yields 30-65% complete responses.6 As no other
simple agent is prospectively proven active against
primary CNS lymphoma, it is presently impossible to
attribute a therapeutic benefit of any single agent apart
from HD MTX. Temozolomide is an oral alkylating agent
that spontaneously undergoes clinical conversion of the
cytotoxic metabolite MTIC (5-[3-methyl-1-triazeno]
imidazole-4-carboxamide) at physiological Ph, without
metabolic conversion. Temozolomide depletes methyl-
transferase in various cell types. Temozolomide activity
against primary CNS lymphoma has been (anecdotally)
reported.7
We present a case of primary CNS lymphoma which
progressed on various chemotherapy regimens but
responded to a single agent temozolomide.
CASE REPORT
A 42 years old gentleman with no medical or family
history presented to Emergency Room in 2007 with a
single episode of generalized tonic clonic seizures
followed by unconsciousness. After regaining conscious-
ness there was no neurological deficit and no lymph
nodes palpable on examination.
The full blood count, calcium, urea, electrolytes and liver
function test were within normal range and the
serological test for human immunodeficiency virus was
negative. MRI brain showed a tumour in the right
temporal region.
The CT scan of neck, chest, abdomen and pelvis were
normal. Craniotomy and biopsy of lesion was consistent
with primary diffuse large B cell lymphoma (high grade).
Tumour showed LCA, CD 20, CD 3 positivity with MIB 1
positive in approximately 90% of neoplastic cell.
The patient was treated with Modified De Angelis
protocol for primary CNS lymphoma. After completion of
therapy, the MRI brain showed increase in size of lesion
in the occipital horn of right ventricle and another on left
side (progression) of disease. In one month, the patient
developed right hemiplegia and aphasia. Patient's   family
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took the option of gamma knife stereotactic surgery,
which lead to further deterioration of his symptoms.
Subsequently he was treated with salvage high dose
methotrexate. Patient improved clinically after two
cycles and MRI also showed responsive disease. After
completion of six cycles imaging showed slight
progression of disease (Figure 1A). At this time he was
switched to salvage temozolomide 150 mg/m2 per orally
daily for 5 days a month.10 After three cycles imaging
showed complete resolution of disease, but patient was
experiencing frequent episode of headaches, so the
dose of temozolomide was decreased to 100 mg/m2. On
completion of his tenth cycle the brain imaging again
showed resolution of disease (Figure 1B).
The patient remained in remission 3 years from his initial
presentation and has a good quality of life. He has no
neurological deficit, has normal mental functions and is
not dependant for daily chores.
DISCUSSION
Primary CNS lymphoma has an aggressive course. The
prognosis of patients with relapse or refractory CNSL is
even poorer and with median survival of only 2 months.8
Methotrexate is the most effective agent against primary
CNS lymphoma. It is used in combination with other
drugs such as vincristine, procarbazine, cytarabine and
rituximab. High dose MTX 3.5 gm/m2 overcomes blood
brain barrier.6 It is followed by consolidation radiation as
initial treatment to maximize response and improve
outcomes. Radiation results in tumour regression as well
as partial repair and closure of blood brain barrier behind
the tumour. HD-MTX in primary CNS lymphoma has
substantially improved the survival of patients with  the
disease.4 Salvage therapy  with HD-MTX appears to be
effective for patients with CNS lymphoma who relapse
after initial complete remission to MTX. In a study,
overall response rate was 91% to first salvage HD-MTX
and 100% to second salvage. Median survival was 61.9
months after first relapse and 91.9 months overall.9
Temozolomide has also been effective as a single agent
as salvage therapy in relapse primary CNS lymphoma.
In a phase-2 trial assessing the activity of TMZ with
recurrent primary CNS lymphoma, previously treated
with HD-MTX containing chemotherapy and radio-
therapy, 9 out of 36 patients had a complete response
(25%; 95% CI 11-39%) and 2 had a partial response
(6%; 95% CI 0-14%). The study was closed at this time
as the target of 10 objective responses were achieved.
Median progression-free survival was 2.8 months
(interquartile range 1-8 months), median overall survival
was 3.9 months (interquartile range 1.7-16 months) and
1-year overall survival was 31% (95% confidence
interval 16-46%).10 In this study 28 patients  (78%) had
first recurrence and only 8 patients had multiple
recurrent disease having failed to respond to other
salvage treatment. Median number of cycles were 2
(range 1-12). Toxicities were mild; 2 patients had
1 episode of grade 4 neutropenia and 1 patient had
grade 3 vomiting in a single cycle. None of the patients
had headaches.
Single-agent temozolomide can be considered as
salvage treatment for patients with primary CNS
lymphoma. It is well tolerated in even patients with
poor performance status. Its non-cumulative and
modest toxicities makes it potentially useful agent for
maintenance therapy.
REFERENCES
1. Schlegel U. Primary CNS lymphoma. Ther Adv Neurol Disord 2009;
2:93-104. 
2. Gerstner ER, Batchelor TT. Primary central nervous system
lymphoma. Arch Neurol 2010; 67:291-7. 
3. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in
primary CNS lymphoma. J Clin Oncol 1998; 16:859-63. 
4. Ferreri AJM, Reni M, Villa E. Therapeutic management of primary
central nervous system lymphoma: lessons from prospective
trials. Ann Oncol 2000; 11:927-37.
5. Ferreri AJM, Reni M, Pasini F, Calderoni A, Terilli U, Pivnik A,
et al. A multicenter study of treatment of primary CNS lymphoma.
Neurology 2002; 58:1513-20.
6. Batchelor TT, Carson K, O'Neill A, Grossman SA, Alavi J, et al.
Treatment of primary CNS lymphoma with methotrexate and
deferred radiotherapy: a report NABTT 96-07. J Clin Oncol 2003;
21:1044-9. 
7. Herrlinger U, Küker W, Platten M, Dichgans J, Weller M. First-
line therapy with temozolomide induces regression of primary
CNS lymphoma. Neurology 2002; 58:1573-4.
8. Renni M, Ferreri AJ, Villa E. Second-line treatment for primary
central nervous lymphoma. Br J Cancer 1999; 79:530-4.
9. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ,
Nabors LB, et al. Treatment of relapsed central nervous lymphoma
with high dose methotrexate. Clin Cancer Res 2004; 10:5643-6.
10. Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, et al.
Temozolomide as salvage treatment in primary central nervous
system lymphoma. Br J Cancer 2007; 96:864-7. 
Figure 1: (A) MRI brain with contrast shows nodular area of the mass
involving the thalamus measuring 2 cm transverse, 2 cm anterioposterior
and 2.1 cm craniocaudal extent as indicated with white arrow (before
Temozolomide). (B) No enhancement seen on contrast to suggest residual/
recurrent disease.
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